These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 9862675)

  • 21. IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands.
    Khoruts A; Osness RE; Jenkins MK
    Eur J Immunol; 2004 Apr; 34(4):1085-90. PubMed ID: 15048719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Purified MHC class I and peptide complexes activate naive CD8+ T cells independently of the CD28/B7 and LFA-1/ICAM-1 costimulatory interactions.
    Goldstein JS; Chen T; Brunswick M; Mostowsky H; Kozlowski S
    J Immunol; 1998 Apr; 160(7):3180-7. PubMed ID: 9531273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
    Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
    J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells.
    Deeths MJ; Mescher MF
    Eur J Immunol; 1997 Mar; 27(3):598-608. PubMed ID: 9079798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.
    Akiba H; Oshima H; Takeda K; Atsuta M; Nakano H; Nakajima A; Nohara C; Yagita H; Okumura K
    J Immunol; 1999 Jun; 162(12):7058-66. PubMed ID: 10358148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of naive CD4 T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of costimulation are critical for a sustained response.
    Rogers PR; Grey HM; Croft M
    J Immunol; 1998 Apr; 160(8):3698-704. PubMed ID: 9558070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation.
    Sperling AI; Auger JA; Ehst BD; Rulifson IC; Thompson CB; Bluestone JA
    J Immunol; 1996 Nov; 157(9):3909-17. PubMed ID: 8892622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals.
    Dubey C; Croft M; Swain SL
    J Immunol; 1996 Oct; 157(8):3280-9. PubMed ID: 8871622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of rat OX40 ligand by monoclonal antibody.
    Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
    Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of CD28 engagement and IL-12 on T cell activation by altered peptide ligands.
    Ding L; Shevach EM
    J Immunol; 1998 Dec; 161(12):6614-21. PubMed ID: 9862689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.
    Kjaergaard J; Tanaka J; Kim JA; Rothchild K; Weinberg A; Shu S
    Cancer Res; 2000 Oct; 60(19):5514-21. PubMed ID: 11034096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective antigen presenting activity of cortical thymic epithelial cells against CD4+ T cells associated with both lack of costimulatory molecules and inefficient presentation of MHC-peptide ligands.
    Kaneda R; Iwabuchi K; Kasai M; Murakami M; Uede T; Onoé K
    Cell Immunol; 1997 Nov; 181(2):163-71. PubMed ID: 9398403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells.
    Croft M; Joseph SB; Miner KT
    J Immunol; 1997 Oct; 159(7):3257-65. PubMed ID: 9317124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein.
    Higgins LM; McDonald SA; Whittle N; Crockett N; Shields JG; MacDonald TT
    J Immunol; 1999 Jan; 162(1):486-93. PubMed ID: 9886424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice.
    McKnight AJ; Perez VL; Shea CM; Gray GS; Abbas AK
    J Immunol; 1994 Jun; 152(11):5220-5. PubMed ID: 7514632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of CD86 in BALB/c mice infected with Leishmania major does not prevent the expansion of low avidity T cells.
    Moro M; Filippi C; Gallard A; Malherbe L; Foucras G; Akiba H; Yagita H; Guéry JC; Glaichenhaus N
    Eur J Immunol; 2002 Dec; 32(12):3566-75. PubMed ID: 12516542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28.
    Hurtado JC; Kim SH; Pollok KE; Lee ZH; Kwon BS
    J Immunol; 1995 Oct; 155(7):3360-7. PubMed ID: 7561030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.